Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
Anne W J MartensJoanne M RietveldRenate de BoerFleur S PetersAn NgoLotte W H G van MilKoen de HeerMarcel SpaargarenChristie P M VerkleijNiels W C J van de DonkHomer C AdamsEric ElderingCarel J M van NoeselRaluca I VeronaArnon P KaterPublished in: Cancer research communications (2022)
Besides reported BCMA expression on multiple myeloma, we demonstrate BCMA can be detected and enhanced using γ-secretase inhibition on cell lines and primary material of various B-cell malignancies. Furthermore, using CLL we demonstrate that low BCMA-expressing tumors can be targeted efficiently using the BCMAxCD3 DuoBody teclistamab.